NCT02039336View on ClinicalTrials.gov

Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

April 2, 2014

Primary Completion Date

August 7, 2018

Study Completion Date

August 7, 2018

Conditions
Colorectal Cancer
Interventions
DRUG

Dacomitinib

DRUG

PD-0325901

DRUG

Docetaxel

Trial Locations (3)

1066CX

The Netherlands Cancer Institute, Amsterdam

3015CE

Erasmus Medical Center Cancer Institute, Rotterdam

3584CX

University Medical Center Utrecht, Utrecht

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

The Netherlands Cancer Institute

OTHER

NCT02039336 - Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC | Biotech Hunter | Biotech Hunter